Description:Anablicum (LGD-4033) is a selective androgen receptor modulator (SARM), discovered by Ligand Pharmaceuticals Inc and perfected by SARMS1. LGD-4033 binds to the androgen receptor of muscle and bone selectively, exhibiting similar effects as testosterone, with only partial agonist activity on the prostate. It was developed as a way to treat diseases or conditions associated with muscle and bone deterioration. The advantage a SARM like LGD has over testosterone is the difference in activity it has on the body outside of muscle and bone.
Anabolicum (LGD-4033) is unarguably the strongest SARM on the market today as far as anabolic power. It adds extra muscle building power to a cutting cycle, strength and size to a bulking cycle, and resilience for the endurance athlete. Used by itself or stacked with one or more other compounds, LGD demands recognition in the world of health, fitness, and bodybuilding.
How it works
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.